Tiltan Pharma For Profit
One of the major advances in cancer research over the past decade has been the realization that tumor growth is dependent on the tumor's ability to recruit blood vessels from the neighboring tissue. Angiogenesis, the process by which new blood vessels are formed, is a hallmark capability of cancer, critical for the development of all solid tumors. This property is the basis for anti-angiogenic therapy, a promising novel strategy for treatment of cancer.
Total Funding:
$1.5M
Headquarters:
Jerusalem, Yerushalayim, Israel
Funding Status:
N/A
Employee Number:
1-10
Investment Stage:
N/A
Last Funding Type:
Venture - Series Unknown
Number Of Exists:
Venture - Series Unknown
Technology:
Biomarker panels
Investor Type:
Company
Founded Date:
2006-01-01
Industry:
Clinical Data Management